Qualitative Concept – Page 42

Mesoblast Secures FDA Approval for Ryoncil, First Mesenchymal Stromal Cell Therapy for Pediatric Steroid-Refractory Acute Graft-Versus-Host Disease

9 months ago talkbio0Tagged Approved, Cell Therapy, Mesenchymal Stromal Cell Therapy, Mesoblast, Pediatric brand name, Ryoncil, SR-aGVHD, Steroid-Refractory Acute Graft-Versus-Host Disease, United States Food and Drug Administration

Mesoblast, Ryoncil, FDA Approval, Mesenchymal Stromal Cell Therapy, Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD), Pediatric Patients, Cell Therapy

FDA Approves Ensartinib for First-Line Treatment of ALK-Positive NSCLC

9 months ago talkbio0Tagged (ALK)-positive, Approved, ensartinib, Holdings, Malignant neoplasm of lung, Non-Small Cell Lung Carcinoma, United States Food and Drug Administration, Xcovery

Ensartinib, ALK-positive NSCLC, FDA approval, lung cancer treatment, Xcovery Holdings

Congress Eyes Major PBM Reforms in Year-End Spending Bill

9 months ago talkbio0Tagged Benefit Managers, bipartisan, Congress, Congress (U.S. Legislature), Health care facility, Legislation, PBMs, Pharmaceutical Services, Pharmacy Benefit Manager, Prices, reforms, spending, Translucent, year-end

Pharmacy Benefit Managers (PBMs), PBM reforms, healthcare costs, year-end spending bill, Congress, bipartisan legislation, transparency, drug prices.

PureTech’s Deupirfenidone Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Patients

9 months ago talkbio0Tagged decline, Force, High, Idiopathic Pulmonary Fibrosis, IPF, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology, Vital capacity, Vital capacity test

Deupirfenidone, Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Forced Vital Capacity (FVC), ELEVATE IPF Phase 2b Trial, PureTech Health

FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns

9 months ago talkbio0Tagged Andexxa, Approved, AstraZeneca, concerns, F10 wt Allele, Hemorrhage, inhibitors, reversal agent, Safety, United States Food and Drug Administration

Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors

FDA Approves Neurocrine’s Crenessity for Rare Congenital Adrenal Hyperplasia

9 months ago talkbio0Tagged Adrenal Glands, Approved, Biosciences, Congenital adrenal hyperplasia, Crenessity, Hereditary Diseases, Neurocrine, United States Food and Drug Administration

Neurocrine Biosciences, FDA approval, Crenessity, crinecerfont, congenital adrenal hyperplasia (CAH), rare genetic disease, adrenal gland condition.

FDA Approves Expanded Use of VTAMA and Nemluvio for Atopic Dermatitis Treatment

9 months ago talkbio0Tagged Approved, Dermatitis, Atopic, Dermatologic disorders, Dermatology field, Galderma, Nemluvio, Organon, United States Food and Drug Administration, Vtama

FDA approval, atopic dermatitis, VTAMA, Nemluvio, Galderma, Organon, dermatology, skin conditions

PureTech’s Deupirfenidone (LYT-100) Demonstrates Superior Efficacy in Slowing Lung Function Decline in Idiopathic Pulmonary Fibrosis (IPF) Phase 2b Trial

9 months ago talkbio0Tagged decline, Fibrosis, High, Idiopathic Pulmonary Fibrosis, Lung, LYT 100, Phase 2b Trial, pirfenidone, PureTech Health, Respiratory physiology

PureTech Health, Deupirfenidone (LYT-100), Idiopathic Pulmonary Fibrosis (IPF), Lung Function Decline, Phase 2b Trial, ELEVATE IPF Trial, Pulmonary Fibrosis Treatment

Reviva’s Brilaroxazine Demonstrates Efficacy and Safety in Long-Term Schizophrenia Treatment

9 months ago talkbio0Tagged Ability to perform cognitive activity, Antipsychotic Agents, Brilaroxazine, Effectiveness, Long-term, Negative, Safety, Schizophrenia, Symptoms aspect

Brilaroxazine, Schizophrenia treatment, Antipsychotic medication, Efficacy and safety, Long-term treatment, Negative symptoms, Cognitive functioning

FDA Approves UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma, Marking a New Era in Skin Cancer Treatment

9 months ago talkbio0Tagged Approved, checkpoint inhibitor, cosibelimab-ipdl, Immunotherapy, Malignant neoplasm of skin, Squamous cell carcinoma, Squamous cell carcinoma of skin, United States Food and Drug Administration, UNLOXCYT

UNLOXCYT, cosibelimab-ipdl, FDA approval, advanced cutaneous squamous cell carcinoma (cSCC), checkpoint inhibitor, immunotherapy, skin cancer treatment.